NurExone Shareholders Back Key Resolutions
EnerSpar Corp. (TSE:NRX) has released an update. NurExone Biologic Inc. shareholders showed strong support for company proposals during the 2024 An...
Source: biztoc.com
📰 Enerspar Corp News
Enerspar Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Enerspar Corp. Real-time updates on events, politics, business and more.
NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided
United States Lior Shaltiel Inbar Paz Benayoun Enerspar Corp Scientific Development Trademark Office
Source: finanznachrichten.de
NurExone Biologic Inc.: NurExone Announces Completion of Securites for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company
Lior Shaltiel Company On Enerspar Corp Nurexone Biologic Inc Enerspar The Company Or Nurexone Alberta Newsfile Corp
Source: finanznachrichten.de
NurExone Biologic Inc.: NurExone Announces Securities for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing
Lior Shaltiel Enerspar Corp Nurexone Biologic Inc Enerspar The Company Or Nurexone Israel Institute Of Technology Alberta Newsfile Corp
Source: finanznachrichten.de
2022-11-24 | TSXV:NRX | Press Release | NurExone Biologic Inc.
(2022-11-24 | TSXV:NRX) NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Israel General United States Hebrew University James Jay Richardson Lior Shaltiel Nurexone Exotherapy
Source: stockhouse.com
NurExone Biologic Inc.: NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome
Israel General United States Hebrew University James Jay Richardson Lior Shaltiel Nurexone Exotherapy
Source: finanznachrichten.de
NurExone announces FDA discussions as they bring hope to millions of spinal cord injury patients
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
United States Lior Shaltiel Nurexone Exotherapy World Health Organization Drug Administration Nurexone Biologic Inc Ltd
Source: econotimes.com
NurExone Biologic Inc.: NurExone Announces Completion of Securities for Debt Settlements
Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company
James Jay Richardson Lior Shaltiel Nurexone Biologic Ltd Company On Enerspar Corp Nurexone Biologic Inc
Source: finanznachrichten.de
NurExone Biologic Inc.: NurExone Announces Additional Securities for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company"
Inbar Paz Benayoun Head Of Communications Enerspar Corp Nurexone Biologic Inc Enerspar The Company Or Nurexone Alberta Newsfile Corp
Source: finanznachrichten.de
NurExone Biologic Inc.: NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided
Source: finanznachrichten.de